CELLINK and CollPlant enter into a collaboration agreement to explore the future large-scale production of CollPlant’s regenerative breast implants using CELLINK’s bioprinting technologies USA – English USA – English

GOTHENBURG, Sweden and REHOVOT, Israel, February 16, 2022 /PRNewswire/ — Today, CELLINK, a BICO Group company (Nasdaq Stockholm: BICO) and a global leader in the development of 3D bioprinting technologies that is expected to bridge the current gap and enable an unlimited supply of vital organs and CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ building, announces the signing of a collaboration agreement. As part of this collaboration, CELLINK’s high-throughput multi-material extrusion bioprinter will be explored for the development of large-scale production of CollPlant’s 3D bioprinted regenerative breast implants, addressing a current market size of $2.8 billionwith 2.2 million procedures performed each year worldwide.

CollPlant has successfully produced prototype 3D bioprinted implants designed to regenerate breast tissue, and is currently evaluating these implants in a series of preclinical studies. Comprised of CollPlant’s rhCollagen and other biological components, the regenerative implants aim to overcome the challenges of existing breast procedures that use silicone implants or autologous adipose tissue transfer. Unlike current approaches, CollPlant’s regenerative implants are designed to degrade over time to be replaced by new, naturally grown breast tissue.

CELLINK, a global leader in bioprinting, is well positioned to support CollPlant’s large-scale bioprinting production process through the use of its printers and technical expertise to address biomanufacturing challenges.

“We are thrilled to work with a partner who shares our values ​​and passion for creating the future of healthcare. We look forward to impacting the breast implant industry, but also to developing a lasting relationship with CollPlant. characterized by advances in the broader field of tissue engineering and regenerative medicine,” said Cecilia Edebo, CEO of CELLINK.

“We are very pleased to partner with CELLINK, a recognized leader in the development of 3D bioprinting solutions for the life science industry,” said CollPlant CEO, Yehiel Tal. “We believe that CELLINK’s high-throughput bioprinters and biofabrication expertise will help us move forward towards the successful commercialization of our technology and provide a much-needed solution to patients around the world.

For more information, please contact:
Gusten DanielssonExecutive Vice President and Chief Financial Officer
Phone (US): +1 (857) 332 2138
Telephone (Sweden): +46 70 991 86 04
E-mail: [email protected]

Eran RotemDeputy General Director
E-mail: [email protected]


CELLINK is creating the future of healthcare as part of BICO, the world leader in bioconvergence. When CELLINK launched the first universal bioink in 2016, it democratized the cost of entry for researchers around the world and played a major role in turning the then booming field of 3D bioprinting into a thriving field. $1 billion industry. Today, the company’s best bio-inks, bio-printers, software and services have been cited in more than 700 publications and are trusted by more than 1,000 academic, pharmaceutical and industrial laboratories. At the forefront of the bioprinting industry, CELLINK aims to alleviate the organ donor shortage with bioengineered transplantable organs and remains committed to reducing our reliance on animal testing and increasing the efficiency of product development. drugs with more physiologically relevant bioprinted organ models. Visit cellink.com to learn more.

About BICO

Founded in 2016, BICO (formerly CELLINK) is the world’s leading bioconvergence company. By combining different technologies, such as robotics, artificial intelligence, computing and 3D bio-printing with biology, we enable our customers to improve people’s health and lives.

The Company is focused on developing technologies that will advance next-generation Health 4.0 core industry ecosystems that enable tissue engineering, diagnostics, multiomics and cell line development. BICO’s technologies enable life science researchers to grow cells in 3D, perform high-throughput drug screening, and print human tissues and organs for the medical, pharmaceutical, and cosmetics industries. We are creating the future of healthcare.

The Group’s instruments in this field amount to 25,000, including the 20 largest pharmaceutical laboratories, are used in more than 65 countries and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com

About Coll Plant

CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. The Company’s products are based on its recombinant human collagen produced with CollPlant’s proprietary plant-based genetic engineering technology. These products meet the indications of the various fields of tissue repair, aesthetics and organ manufacturing, and usher in a new era of regenerative and aesthetic medicine.

In early 2021, CollPlant entered into a global development and commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, a global leader in the dermal fillers market. Later in 2021, CollPlant entered into a strategic co-development agreement with 3D Systems for a 3D bio-printed regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant.

For more information, visit http://www.collplant.com

Safe Harbor for forward-looking statements

This press release may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant’s goals, plans and strategies, as well as statements, other than of historical fact, that address activities, events or developments that CollPlant intends, expects, projects, believes or forecasts that it will or may occur in the future. These statements are often characterized by terms such as “believes”, “hopes”, “may”, “anticipates”, “should”, “intends”, “plans”, “will”, “expects”. to”, “estimates”, “projects”, “positioned”, “strategy” and similar expressions and are based on assumptions and assessments made in light of experience and management’s perception of historical trends, current conditions, expected future developments and other factors deemed appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Many factors could cause CollPlant’s actual operations or results to differ materially from the operations and results anticipated in the forward-looking statements, including, but not limited to, the following: CollPlant’s history of significant losses and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, if at all; CollPlant’s expectations regarding the timing and cost of initiating clinical trials for tissues and organs based on its rhCollagen-based BioInk; the ability of CollPlant or its business partners to obtain favorable preclinical and clinical trial results; regulatory action regarding rhCollagen-based BioInk, including but not limited to the acceptance of a marketing authorization application, the review and approval of such application and, if is approved, scope of indication and labeling approved; the commercial success and market acceptance of CollPlant’s rhCollagen-based BioInk; CollPlant’s ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third-party distributors and resellers; CollPlant’s ability to establish and maintain strategic partnerships and other corporate collaborations; CollPlant’s reliance on third parties to carry out certain aspects of the manufacturing of its products; the extent of protection CollPlant is able to establish and maintain for intellectual property rights and the company’s ability to conduct business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political and economic conditions in the countries in which the company operates; capital expenditures and projected cash; changes in corporate strategy; and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant is contained under the heading “Risk Factors” included in CollPlant’s most recent Annual Report on Form 20-F, and in other periodic filings by CollPlant with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant’s current views with respect to future events, and the company undertakes, and specifically disclaims, any obligation to update update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Comments are closed.